Navigation Links
Report recommends off-site disposal of secondary waste
Date:9/2/2007

hey are analyzed for contaminants, treated if necessary, and disposed of either on- or off-site. The committee found that disposal of these spent solutions does not present a significant challenge for the currently operating facilities, and so does not require any changes at this time.

In addition to secondary wastes, the report examines the regulatory requirements associated with trial burns at the incinerator facilities. Trial burns are used to ensure that 99.9999 percent of the toxic agents will be destroyed during regular operations. The time required to complete a trial burn, submit results, and obtain authorization for full operation can be very lengthy due to the time required to actually conduct the burn and the large amount of data that must be submitted and analyzed. However, under the Resource Conservation and Recovery Act (RCRA), which governs the disposal operations, these trials can potentially be avoided through the submission of data from a trial burn conducted in a sufficiently similar incinerator burning the same agent.

The committee found that because a trial burn has occurred for each type of incinerator with each agent, enough data exists to avoid further trial burns in many cases. The report recommends using this process of data submission in lieu of a trial burn to the fullest extent possible. The committee also recommends that the CMA should try to provide funding to state authorities for third-party analysis of trial burn data to shorten the time necessary for approval.


'/>"/>
Contact: Paul Jackson
news@nas.edu
202-334-2138
The National Academies
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
3. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
4. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. In Vivo Signal Transduction Pathway Reporting Systems
7. Improved Vectors for PathDetect Trans-Reporting Systems
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. Cis-Reporting System Monitors Intracellular Calcium Mobilization
10. Cis-Reporting System Monitors Intracellular Calcium Mobilization
11. PatchMan - Test Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...FirstCall/ -- AstraZeneca (NYSE:,AZN) today announ...A) has,approved once-daily SEROQUEL XR(R) (quetiap...te treatment of the depressive episodes associated...es associated with bipolar I,disorder, and the mai...tive,therapy to lithium or divalproex. SEROQUEL XR...
(Date:10/10/2008)...Takeda Pharmaceutical Company,Limited ("Takeda") t...elopment Center, Inc., a wholly owned United State...e U.S. Food and Drug Administration (FDA) will,not...New Drug Application,(NDA) by the Prescription Dru... "In our most recent discussion with the FDA, it i...
(Date:10/9/2008)...up six spots from last year, ST. LOUIS, Oct. 9 /P...N) is earning recognition as a leader in biotechno... also for being a great place to work., Monsanto,... place in,the 2008 Top Biotech and Pharma Employer... The company moved up six spots from number eight ...
(Date:10/9/2008)... - Dr. Brad Thompson, President,and CEO of Oncolyt...esent a,corporate overview of the Company at the 1...on, U.K. on Monday, October 13 at 2 p.m. The confe...nference Centre from October,12-14, 2008., About ...based biotechnology company focused on the,develop...
Breaking Biology Technology:FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 2FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 3FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 4FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 5FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 6FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 7FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 8FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 9FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Monsanto Recognized as Top Biotechnology Employer by Science Magazine 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2
... stories to tell, but perhaps nothing is more illu...ory of a little girl drawing in the back of a clas...ul Getty Trust in Los Angeles and an internationa..., told the story during a keynote address at the a...Association Conference. , ,Noting that young chil...
...ago Bar Association entitled "Communication Rights...t Century." At that time, many who attended thou...faith in it. My argument was that the horse-and-bu...d liquor were maxed out. Municipalities would have...ms that could pay for services and pensions. , ,Th...
...n Internet data provider, has appointed its legal ...ions officer. , ,Meier brings experience in the le...and he will be responsible for helping the Milwauk...and business development programs. , ,"I believe i...go when it was just two people and an idea," Donat...
...and his company through a series of mergers and pe...der of JT Packard & Associates, Inc. , Cason pres...er. The company has grown by 500 percent over the ...ptible power supply (UPS) service company in the c...,With its recent purchase by Anaheim, Calif.-based...
Other Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4Power services firm JT Packard isn't through growing 2Power services firm JT Packard isn't through growing 3
(Date:10/10/2008)...ry researchers have found that statins may be able...g from pregnancy complications caused by antiphosp...ce. In this autoimmune syndrome, the body produces...mponents of cell membranes. This news comes from a...nal of Clinical Investigation that is currently o...
(Date:10/10/2008)...f Kyoto University and the Gladstone Institute of ...ep forward in improving the possibilities for the ...(iPS) cell technology. , Previously, Dr. Yamanak...o become embryonic stem celllike using a cancer-ca...o reprogram the cells, and a virus to transfer the...
(Date:10/10/2008)..., Gasterosteus aculeatus , is one of the most tho...n a particularly useful model for understanding va...morphology caused by different ecological situatio...cular and genetic to developmental and morphologic...it has proven far more complex than even imagined....
(Date:10/10/2008)... in German . , DNA, the molecule that acts as...f life, is highly resistant against alteration by ... for its photostability presents some puzzling pro... four chemical bases that make up the DNA molecule... showing that DNA strands differ in their light se...
Breaking Biology News(10 mins):Statins may prevent miscarriages 2Statins may prevent miscarriages 3Yamanaka eliminates viral vector in stem cell reprogramming 2Fitness in a changing world 2Fitness in a changing world 3Can genetic information be controlled by light? 2Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4Viscosity Enhancers Curb Bleeding Complications 17971 1Viscosity Enhancers Curb Bleeding Complications 17971 2Genes Linked to Osteoporosis Identified 17967 1Genes Linked to Osteoporosis Identified 17967 2Genes Linked to Osteoporosis Identified 17967 3
...f Medicine researchers have discovered how new neu...nt to regions of the brain where they can replace ...tem cell therapies can be specifically targeted to...ses or by stroke. , Associate Professor Qun-Yong Z...artment of Pharmacology have identified a protein ...
... the world are breathing a sigh of relief, as they...ir natural disease-fighting substances. Scientists... didemnii, which lives symbiotically inside the se...es, compounds that may one day be used in cancer t...s could not successfully cultivate Prochloron in t...
...sma protein found in blood, can be fused with larg...stimulating factor (G-CSF) to create a new oral co...rough the gastrointestinal (GI) tract and then abl... the body, according to research from the Universi...is technology may allow for oral administration of...
...factors prove that BioMed Central,s Open Access jo... Journals published by BioMed Central have again r...valent subscription titles, it was announced today...lty. The high impact factors for these journals af...re fast becoming the place for authors to submit i...
Other Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 3'Bionic' arm gives amputee sense of touch 2
...itivity Laboratory Osmometer for both 0.2 and 2.0 ...ludes built-in printer, keypad, and software for s...reading capability with optional scanner. RS-232 p...Two-step Calibration. ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor
Recombinant Rat CINC-2 alpha, CF
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice
Biology Products: